TTKHLTCARE

TTK Healthcare Share Price

₹1,448.35 -16.75 (-1.14%)

21 Nov, 2024 16:48

SIP TrendupStart SIP in TTKHLTCARE

Start SIP

Performance

  • Low
  • ₹1,440
  • High
  • ₹1,465
  • 52 Week Low
  • ₹1,272
  • 52 Week High
  • ₹1,894
  • Open Price₹1,465
  • Previous Close₹1,465
  • Volume2,629

Investment Returns

  • Over 1 Month -12.22%
  • Over 3 Month -11.72%
  • Over 6 Month -4.42%
  • Over 1 Year + 9.98%
SIP Lightning

Smart Investing Starts Here Start SIP with TTK Healthcare for Steady Growth!

Invest Now

TTK Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.6
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 2,047
  • P/B Ratio
  • 2.1
  • Average True Range
  • 45.51
  • EPS
  • 45.79
  • Dividend Yield
  • 0.7
  • MACD Signal
  • -40.26
  • RSI
  • 37.37
  • MFI
  • 25.73

TTK Healthcare Financials

TTK Healthcare Technicals

EMA & SMA

Current Price
₹1,448.35
-16.75 (-1.14%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹1,513.54
  • 50 Day
  • ₹1,565.66
  • 100 Day
  • ₹1,567.91
  • 200 Day
  • ₹1,519.45

Resistance and Support

1456.35 Pivot Speed
  • R3 1,526.65
  • R2 1,500.30
  • R1 1,482.70
  • S1 1,438.75
  • S2 1,412.40
  • S3 1,394.80

What's your outlook on TTK Healthcare?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

TTK Healthcare Ltd. operates across diverse sectors, offering pharmaceuticals, medical devices, consumer products, and animal care solutions. With a strong presence in India, it provides trusted healthcare and wellness products that cater to both domestic and global markets.

T T K Healthcare (Nse) has an operating revenue of Rs. 771.29 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 11% is healthy, ROE of 6% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

TTK Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-08-02 Quarterly Results
2024-05-24 Audited Results & Final Dividend
2024-02-02 Quarterly Results
2023-11-03 Quarterly Results

TTK Healthcare F&O

TTK Healthcare Shareholding Pattern

74.56%
0%
1.9%
0.01%
16.02%
7.51%

About TTK Healthcare

  • NSE Symbol
  • TTKHLTCARE
  • BSE Symbol
  • 507747
  • ISIN
  • INE910C01018

Similar Stocks to TTK Healthcare

TTK Healthcare FAQs

TTK Healthcare share price is ₹1,448 As on 21 November, 2024 | 16:34

The Market Cap of TTK Healthcare is ₹2046.6 Cr As on 21 November, 2024 | 16:34

The P/E ratio of TTK Healthcare is 25.6 As on 21 November, 2024 | 16:34

The PB ratio of TTK Healthcare is 2.1 As on 21 November, 2024 | 16:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23